Top entities: AstraZeneca, Levi & Korsinsky, Joseph E. Levi, China.

What category does this event fall under?

Business — classified as class action lawsuit.

What is the sentiment of coverage?

Aggregate sentiment score: -50 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

Levi & Korsinsky notified investors of lawsuit AstraZeneca · AstraZeneca engaged in insurance fraud China · AstraZeneca understated legal risks

Is this event still developing?

This event is archived — the story has concluded and this page is a final snapshot.

Business class action lawsuit

AstraZeneca sued for securities fraud

Q: When did this event occur?

First reported Jan 08, 2025; last updated Jan 22, 2025.

Q: What is the market impact?

General. The market is impacted by the potential financial and reputational damage to AstraZeneca due to the class action lawsuit and allegations of insurance fraud in China.

Analysis based on 7 articles · First reported Jan 08, 2025 · Last updated Jan 22, 2025

Sentiment

-50

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The market is impacted by the potential financial and reputational damage to AstraZeneca due to the class action lawsuit and allegations of insurance fraud in China. Investors are seeking to recover losses, indicating a negative outlook on AstraZeneca's stock price and future business prospects in China.

Pharmaceuticals Legal Services

Event Summary

A class action securities lawsuit has been filed against AstraZeneca by Levi & Korsinsky, alleging that AstraZeneca engaged in insurance fraud in China between February 23, 2022, and December 17, 2024. The lawsuit claims that AstraZeneca made false statements and concealed its heightened legal exposure in China, which resulted in the detention of its China President by Chinese law enforcement authorities. These allegations, once revealed, are expected to materially harm AstraZeneca's business activities in China and have led to investors suffering losses. The deadline for investors to request to be appointed as lead plaintiff is February 21, 2025.